Calamos Advisors LLC Sells 25,475 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Calamos Advisors LLC trimmed its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 30.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,527 shares of the company’s stock after selling 25,475 shares during the quarter. Calamos Advisors LLC’s holdings in GeneDx were worth $4,575,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. MCF Advisors LLC grew its stake in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. CWM LLC purchased a new position in shares of GeneDx during the third quarter valued at about $89,000. Evolution Wealth Advisors LLC bought a new stake in shares of GeneDx in the fourth quarter worth about $202,000. PFG Investments LLC purchased a new stake in shares of GeneDx in the fourth quarter worth about $252,000. Finally, SG Americas Securities LLC bought a new position in GeneDx during the third quarter valued at approximately $198,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder School Of Medicine At Mo Icahn sold 20,359 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $69.78, for a total value of $1,420,651.02. Following the sale, the insider now directly owns 2,846,474 shares in the company, valued at approximately $198,626,955.72. This represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $76.37, for a total value of $86,832.69. Following the sale, the chief financial officer now directly owns 24,731 shares of the company’s stock, valued at $1,888,706.47. This represents a 4.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 363,669 shares of company stock valued at $28,061,081. 27.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on WGS shares. TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th. Wells Fargo & Company boosted their price target on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Finally, Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.67.

GeneDx Stock Performance

NASDAQ:WGS opened at $72.02 on Wednesday. The firm has a market capitalization of $1.98 billion, a PE ratio of -23.16 and a beta of 2.01. The stock’s fifty day moving average is $77.91 and its 200 day moving average is $58.87. GeneDx Holdings Corp. has a fifty-two week low of $3.63 and a fifty-two week high of $98.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.